- Home
- KRYS
KRYS
Krystal Biotech Inc.
as 11-14-2024 12:35pm EST
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 5.1B | IPO Year: | 2017 |
| Target Price: | $199.43 | AVG Volume (30 days): | 236.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $96.73 - $219.34 | Next Earning Date: | 11-04-2024 |
| Revenue: | $241,519,000 | Revenue Growth: | 2722.80% |
| Revenue Growth (this year): | 485.65% | Revenue Growth (next year): | 58.64% |
Stock Insider Trading Activity of Krystal Biotech Inc. (KRYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Krishnan Krish S | KRYS | President and CEO | Sep 12 '24 | Sell | $198.43 | 50,000 | $9,888,276.35 | 1,500,882 | |
| Krishnan Suma | KRYS | President, R&D | Sep 12 '24 | Sell | $198.43 | 50,000 | $9,888,276.35 | 1,517,385 |
Latest Krystal Biotech Inc. News
KRYS Breaking Stock News: Dive into KRYS Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
KRYS: Raising target price to $197.00
Simply Wall St.
3 days ago
High Growth Tech Stocks Featuring Three Prominent US Companies
GlobeNewswire
3 days ago
Krystal Biotech to Present at Stifel 2024 Healthcare Conference
Simply Wall St.
4 days ago
US Exchange Highlights 3 Growth Stocks With Strong Insider Ownership
Simply Wall St.
8 days ago
Krystal Biotech, Inc. (NASDAQ:KRYS) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
GlobeNewswire
9 days ago
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Argus Research
10 days ago
KRYS: Lowering target price to $183.00
Zacks
10 days ago
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
Compare KRYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRYS Krystal Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.